Research profile
Semaglutide
Semaglutide activates the GLP-1 receptor and influences glucose regulation and appetite.
- Phase 3 clinical trial
- Evaluation only
Amnavero
Semaglutide
What the research found
In STEP 1, 1,961 adults with obesity or overweight without diabetes received semaglutide or placebo alongside a lifestyle intervention. At 68 weeks, average weight change was −14.9% versus −2.4%.
What remains uncertain
The result applies to the injectable formulation and study population. Different approved semaglutide formulations have their own indications.